WS #16223
Thermo Fisher Scientific (TMO) and Elevance Health (ELV) reported third-quarter earnings that substantially exceeded analyst expectations, with TMO posting a 4.4% EPS beat and ELV delivering a massive 49% EPS surprise. Thermo Fisher's 15% biopharma growth and Elevance's raised full-year guidance underscore strong demand in life sciences and health insurance. This earnings strength supports a defensive rotation into healthcare and scientific instruments, contrasting with the volatility seen in consumer-facing tech.
Healthcare and Life Sciences Earnings
Thermo Fisher Scientific (TMO) and Elevance Health (ELV) reported third-quarter earnings that substantially exceeded analyst expectations, with TMO posting a 4.4% EPS beat and ELV delivering a massive 49% EPS surprise. Thermo Fisher's 15% biopharma growth and Elevance's raised full-year guidance underscore strong demand in life sciences and health insurance. This earnings strength supports a defensive rotation into healthcare and scientific instruments, contrasting with the volatility seen in consumer-facing tech.